Follow the evidence
Public sources checked October 5, 2026. Trial abstracts support only the limited summaries identified in the article. Provider pages document advertised offers.
- FDA — Zepbound approval and dual receptor activityHistorical approval announcement; mechanism context
- MedlinePlus — tirzepatide injectionFederal patient drug information
- Aronne et al. — SURMOUNT-5, NEJM 2025 (PubMed abstract)Randomized trial; abstract reviewed, not full-text appraisal
- Frías et al. — SURPASS-2, NEJM 2021 (PubMed abstract)Randomized diabetes trial; abstract reviewed
- CoreAge Rx — official treatment pagesProvider offer
- CoreAge Rx — tirzepatide offerProvider offer
- CoreAge Rx Help Center — Pricing & PlansProvider billing terms
- SuperHealthy Rx — current GLP-1 offerProvider offer
- Likeness Rx — GLP-1 plans and billingProvider offer
- Ro Body — membership and medication costsProvider offer
- WeightWatchers — Med+ membership and medicationProvider offer
- LillyDirect — pharmacy access and independent care optionsManufacturer access program
- FDA — concerns with unapproved GLP-1 drugsRegulator guidance
- FDA — compounding questions and answersRegulator guidance
- FDA — dosing errors with compounded injectable semaglutideSafety alert, July 2024
- NIDDK — prescription medications for overweight and obesityFederal patient education